Strong data in a second Phase III study of Ardelyx Inc.'s investigational treatment for constipation-predominant irritable bowel syndrome (IBS-C), tenapanor, have put the product back on track, and could prove to be transformational for the company. Shares in the firm were up by more than 48% on NASDAQ on the data, restoring some of the value lost back in May when the first Phase III study T3MPO-1 results underwhelmed investors.
Ardelyx's next steps are to seal licensing deal for the product ahead of a planned NDA filing in the second...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)